SCHEMBL20914151

SCHEMBL20914151

COc1cc(C#N)cc2oc(-c3c(C)[nH]c4c(-c5ccccc5)c(C(F)(F)F)nn4c3=O)nc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ARF6 P62330 4/20 0.37
▸ KDM4E B2RXH2 3/20 0.35
▸ POLB P06746 2/20 0.35
▸ HTT P42858 2/20 0.33
▸ HPGD P15428 3/20 0.32
▸ NPSR1 Q6W5P4 2/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ TSHR P16473 1/20 0.32
▸ DCTPP1 Q9H773 1/20 0.31
▸ PLAT P00750 1/20 0.31
▸ STK10 O94804 1/20 0.31
▸ SLK Q9H2G2 1/20 0.31
▸ MAPT P10636 2/20 0.31
▸ KCNQ3 O43525 1/20 0.31
▸ KCNQ2 O43526 1/20 0.31
▸ CRHBP P24387 1/20 0.31
▸ CRHR2 Q13324 1/20 0.31
▸ ALDH1A1 P00352 2/20 0.30
▸ L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914011 0.90 KDM4E (0.38) ARF6KDM4EPOLBNPSR1MEN1
SCHEMBL20914066 0.89 ARF6 (0.39) ARF6KDM4EPOLBNPSR1MEN1
SCHEMBL20914015 0.88 POLB (0.37) ARF6KDM4EPOLBNPSR1MEN1
SCHEMBL20914246 0.87 ARF6 (0.34) ARF6KDM4EPOLBHTTHPGD
SCHEMBL20914408 0.87 KDM4E (0.36) ARF6KDM4EPOLBNPSR1MEN1
SCHEMBL20914222 0.87 KDM4E (0.36) ARF6KDM4EPOLBHPGDNPSR1
SCHEMBL20914005 0.87 POLB (0.36) ARF6KDM4EPOLBMEN1KMT2A
SCHEMBL20914096 0.87 ARF6 (0.39) ARF6PLATMAPTALDH1A1
SCHEMBL20914245 0.87 KDM4E (0.36) ARF6KDM4EPOLBNPSR1MEN1
SCHEMBL20819069 0.86 TNKS (0.37) ARF6KDM4EPOLBHTTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
CN-111212839-A Pyrazolopyrimidinone compounds and uses thereof 艾杜罗生物科技公司 2020-05-29 — — CN disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 ARF6 3310/4885KDM4E 1922/4885POLB 4311/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 ARF6 3310/4885KDM4E 1922/4885POLB 4311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback